CoChat
Sign Up
Cited by 98

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future

Shimada, Yuichi J., Cannon, Christopher P.·2015·European Heart Journal
DOI 10.1093/eurheartj/ehv174
Open this paper in CoChat — free account

Abstract

Reduction in low-density lipoprotein cholesterol (LDL-C), mainly with statins, has decreased the risk of cardiovascular events over the last few decades. However, there are several patient populations that warrant further decrease in LDL-C by additional cholesterol-lowering therapy other than statins. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are a new class of drugs that have been shown to further decrease LDL-C by 50-70% when administered as a monotherapy or on a background therapy with statins. Proprotein convertase subtilisin/kexin type 9 inhibitors are also an excellent example of drug development in which discovery of gene mutations and its clinical effects have rapidly progressed into successful preclinical and clinical studies with multiple Phases 1-3 clinical trials completed or ongoing to date. This review summarizes the rapid evolution of the drug from genetic discovery to identification of targets for the drugs, to animal and human testing, and to large clinical outcomes trials, followed by discussion on foreseeable challenges of PCSK9 inhibitors.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv174

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 6 references

Research works printed but not linked: 65

  1. 10.1373/clinchem.2010.159350 · DOI
  2. 10.1161/CIRCOUTCOMES.110.959247 · DOI · Paper page
  3. 10.1016/S0140-6736(05)67394-1 · DOI · Paper page
  4. 10.1007/s00392-006-0403-x · DOI · Paper page
  5. 10.1016/j.jacc.2009.10.042 · DOI
  6. 10.1042/bse0380079 · DOI
  7. 10.1073/pnas.0335507100 · DOI · Paper page
  8. 10.1016/j.abb.2003.09.011 · DOI
  9. 10.1074/jbc.M409699200 · DOI · Paper page
  10. 10.1038/nsmb1235 · DOI · Paper page
  11. 10.1038/ng1161 · DOI · Paper page
  12. 10.1002/humu.9383 · DOI
  13. 10.1007/s00109-005-0019-z · DOI
  14. 10.1097/01.mol.0000162321.31925.a3 · DOI · Paper page
  15. 10.1136/jmg.2006.038356 · DOI · Paper page
  16. 10.1016/j.jacc.2010.02.044 · DOI
  17. 10.1016/j.atherosclerosis.2006.08.039 · DOI
  18. 10.1161/CIRCGENETICS.108.828467 · DOI
  19. 10.1016/j.atherosclerosis.2008.03.009 · DOI
  20. 10.1161/ATVBAHA.109.194191 · DOI
  21. 10.1086/507488 · DOI
  22. 10.1073/pnas.0903849106 · DOI · Paper page
  23. 10.7150/ijbs.3524 · DOI
  24. 10.1194/jlr.M011445 · DOI
  25. 10.1073/pnas.0805434105 · DOI
  26. 10.1016/S0140-6736(13)61914-5 · DOI
  27. 10.1371/journal.pone.0010682 · DOI · Paper page
  28. 10.1194/jlr.C600025-JLR200 · DOI
  29. 10.1038/mt.2011.260 · DOI
  30. 10.1007/s11886-013-0391-1 · DOI
  31. 10.1074/jbc.M702027200 · DOI · Paper page
  32. 10.1172/JCI29383 · DOI · Paper page
  33. 10.1016/j.bbrc.2008.04.004 · DOI
  34. 10.1073/pnas.0409736102 · DOI · Paper page
  35. 10.1073/pnas.0501652102 · DOI · Paper page
  36. 10.1373/clinchem.2007.091280 · DOI
  37. Tavori, 2014, On the function and homeostasis of PCSK9: Reciprocal interaction with LDLR and additional lipid effects, Atherosclerosis, 238, 264, 10.1016/j.atherosclerosis.2014.12.017 · DOI · Paper page
  38. 10.1016/j.jacc.2012.03.007 · DOI
  39. 10.1016/S0140-6736(12)61770-X · DOI
  40. 10.1016/j.jacc.2012.08.986 · DOI
  41. 10.1056/NEJMoa1201832 · DOI
  42. 10.1001/jama.2014.4030 · DOI · Paper page
  43. 10.1016/j.ijcard.2014.06.049 · DOI
  44. 10.1161/CIRCULATIONAHA.113.007012 · DOI
  45. Cannon, 2015, Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial, Eur Heart J, 10.1093/eurheartj/ehv028 · DOI
  46. 10.1093/eurheartj/eht273 · DOI · Paper page
  47. 10.1016/j.atherosclerosis.2007.12.024 · DOI
  48. 10.1111/j.1365-2796.2004.01405.x · DOI
  49. 10.1016/j.amjcard.2008.07.035 · DOI
  50. 10.1016/j.atherosclerosis.2009.09.014 · DOI · Paper page
  51. Robinson, 2013, Management of familial hypercholesterolemia: a review of the recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia, J Manag Care Pharm, 19, 139, 10.18553/jmcp.2013.19.2.139 · DOI
  52. 10.1016/j.jacc.2004.03.046 · DOI
  53. 10.1161/01.cir.0000457464.79076.2c · DOI
  54. 10.1586/14779072.6.7.955 · DOI · Paper page
  55. Bays, 2014, Efficacy and safety of combining alirocumab with atorvastatin or rosuvastatin versus statin intensification or adding ezetimibe in high cardiovascular risk patients: ODYSSEY OPTIONS I and II, Circulation, 130, 2118
  56. Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies. http://www.escardio.org/congresses/esc-2014/congress-reports/Pages/707-3-Hotline3-ODYSSEY-COMBO-FH.aspx#presenter2 (28 April 2015). · DOI
  57. Etemad, 2005, Total first-year costs of acute coronary syndrome in a managed care setting, J Manag Care Pharm, 11, 300, 10.18553/jmcp.2005.11.4.300 · DOI
  58. 10.1503/cmaj.101281 · DOI
  59. 10.1007/s11936-006-0049-z · DOI
  60. 10.1185/03007990903494934 · DOI
  61. 10.1056/NEJMoa1501031 · DOI · Paper page
  62. 10.1016/j.jacc.2013.07.056 · DOI
  63. 10.1038/nrcardio.2014.84 · DOI
  64. Koren, 2015, Safety and efficacy of alirocumab 150 mg every 2 weeks, a fully human proprotein convertase subtilisin/kexin type 9 monoclonal antibody: A Phase II pooled analysis, Postgrad Med, 127, 125, 10.1080/00325481.2015.998987 · DOI
  65. 10.3390/nu6125517 · DOI

Cited by

Sorted by citations

See all 98

Metadata

Authors
Shimada, Y. J., & Cannon, C. P.
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2015-05-12
Volume
36
Issue
36
Pages
2415-2424
ISSN
  • 0195-668X
  • 1522-9645
DOI
10.1093/eurheartj/ehv174
Cited by
98
References
6
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review